FCF Healthcare & Life Sciences Venture Capital Monitor - Europe - Published in June 2026

The FCF Healthcare & Life Sciences Venture Capital Monitor – Europe is a monthly overview of financing trends in the venture capital sector, with a focus on European healthcare and life sciences companies.

As of the end of June 2026, we have identified the following current VC trends in Europe:

• Total Healthcare & Life Sciences funding reached EUR 6,158m (-5% vs. 2025)

• Biotech/Pharma received 36% of the total investment volume (EUR 2,227m), with oncology being the leading indication (37%)

• In June, Bionyra (FR) secured the highest transaction volume with EUR 143m, followed by RQ Bio (UK) with EUR 99m and Ona Therapeutics (ES) with EUR 74m

• GV (US) is the most active investor (by deal volume in 2026), followed by Alphabet (US) and CapitalG (US)

To read the full report, click here.